Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells

Journal of Clinical Investigation

Volumn 109, Issue 11, 2002, Pages 1463-1470

  Wang, Helen Y ^a   Fu, Tihui ^a   Wang, Gang ^b   Zeng, Gang ^b   Perry Lalley, Donna M ^b   Yang, James C ^b   Restifo, Nicholas P ^b   Hwu, Patrick ^b   Wang, Rong Fu ^a,c  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; GENE DELIVERY SYSTEM; GENETIC TRANSDUCTION; KNOCKOUT MOUSE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, TAT; IMMUNOTHERAPY; LIPID BILAYERS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036266363     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200215399     Document Type: Article

References (50)

1. Human tumor antigens for cancer vaccine development
2. Dendritic cells and the control of immunity
3. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
4. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
5. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
6. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells
7. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
8. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
9. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model
10. The dendritic cell and human cancer vaccines
11. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues
12. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma
13. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
14. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
15. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
16. Cellular uptake of the tat protein from human immunodeficiency virus
17. Intercellular trafficking and protein delivery by a herpesvirus structural protein
18. Intercellular delivery of functional p53 by the herpesvirus protein VP22
19. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence
20. Genetic engineering of proteins with cell membrane permeability
21. Tat-mediated delivery of heterologous proteins into cells
22. In vivo protein transduction: Delivery of a biologically active protein into the mouse
23. Cell-penetrating peptides
24. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells
25. Immunity against cancer: Lessons learned from melanoma
26. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
27. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
28. Dendritic cells retrovitally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
29. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
30. Elucidaring the autoimmune and antitumor effector mechanisms of a rrearment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy
31. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
32. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
33. Coupling and uncoupling of tumor immunity and autoimmunity
34. Role of dendritic cells in the induction and maintenance of autoimmune diseases
35. Insertion signal sequence fused to minimal peptides elicits specific CD8- T-cell responses and prolong survival of thymoma-bearing mice
36. Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1
37. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells
38. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
39. CD4+ T cells orchestrate both amplification and deletion of CD8+ T cells
40. The role of CD4(+) T cell responses in antitumor immunity
41. CD4 T cells and their role in antitumor immune responses
42. Inflammatory stimuli induce accumulation of MHC class 11 complexes on dendritic cells
43. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA
44. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen
45. Introduction of soluble proteins into the MHC class 1 pathway by conjugation to an HIV tat peptide
46. Immunotherapy of human cancer: Lessons from mice
47. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
48. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity
49. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells
50. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity